Buck Institute for Research on Aging
Latest From Buck Institute for Research on Aging
Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
New research has identified ApoE as a potential direct regulator of transcription, suggesting a broad role for the molecule in the study of Alzheimer’s disease that could explain why the usual strategies of trying to break up accumulations of amyloid beta or regulate tau hyperphosphorylation have failed to adequately treat symptoms or cure the disease.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.